Afuco™ Anti-Human CLEC2D ADCC Therapeutic Antibody, ADCC Enhanced
Anti-CLEC2D ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. This is a monoclonal antibody that is capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-163CL |
| Pricing | Inquiry |
| Host | Chimeric (human/mouse) |
| Target | CLEC2D |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | ≤1 year at -20°C. |